LINC00152 Promotes Tumor Progression and Predicts Poor Prognosis by Stabilizing BCL6 From Degradation in the Epithelial Ovarian Cancer

Wang, Shunni; Weng, Wei-Hung; Chen, Tingting; Xu, Ming; Wei, Ping; Li, Jing; Lu, Linghui; Wang, Yiqin

doi:10.3389/fonc.2020.555132

Cited by 14 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, higher expression of LINC00152 in children with B-ALL was associated with a higher risk of early relapse; conversely, lower expression of LINC01013 was associated with early relapse. The lncRNA LINC00152 is also known as CYTOR (long non-coding RNA cytoskeleton regulator RNA) and has been previously described as an oncogenic lncRNA in many different types of cancer (e.g., [ 92 , 93 , 94 , 95 , 96 , 97 ]) and may serve as a potential biomarker for cancer detection in both solid tumor tissue and plasma [ 98 , 99 ]. Overall, these reports indicate that lncRNA expression can serve as useful biomarkers in B-ALL.…”

Section: Long Non-coding Rnas In Progenitor B-cell Acute Lymphoblamentioning

confidence: 99%

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Rodriguez

Paculova

Kogut

et al. 2021

IJMS

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) comprise a diverse class of non-protein coding transcripts that regulate critical cellular processes associated with cancer. Advances in RNA-sequencing (RNA-Seq) have led to the characterization of non-coding RNA expression across different types of human cancers. Through comprehensive RNA-Seq profiling, a growing number of studies demonstrate that ncRNAs, including long non-coding RNA (lncRNAs) and microRNAs (miRNA), play central roles in progenitor B-cell acute lymphoblastic leukemia (B-ALL) pathogenesis. Furthermore, due to their central roles in cellular homeostasis and their potential as biomarkers, the study of ncRNAs continues to provide new insight into the molecular mechanisms of B-ALL. This article reviews the ncRNA signatures reported for all B-ALL subtypes, focusing on technological developments in transcriptome profiling and recently discovered examples of ncRNAs with biologic and therapeutic relevance in B-ALL.

show abstract

Section: Long Non-coding Rnas In Progenitor B-cell Acute Lymphoblamentioning

confidence: 99%

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Rodriguez

Paculova

Kogut

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Jiang et al demonstrated the carcinogenic role of the lncRNA XIST in OC and showed that high expression of XIST indicates a poor prognosis for OC patients ( 32 ). Moreover, studies showed that dysregulation of LINC00152 is a risk factor for poor outcome in patients with OC ( 33 ) and the lncRNA E2F4as predicts poor prognosis and promotes OC progression ( 34 ). These results demonstrate that lncRNAs are promising prognostic markers in OC.…”

Section: Discussionmentioning

confidence: 99%

A ferroptosis-related lncRNA signature predicts prognosis in ovarian cancer patients

Peng¹,

Hu²,

Rao³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Ovarian cancer (OC) is a common gynecological malignant tumor with poor prognosis.Ferroptosis is an iron-dependent modality of regulated cell death. The purpose of this study was to determine the prognostic ability of ferroptosis-related long non-coding RNAs (lncRNAs) in OC patients and construct a ferroptosis-related lncRNA prognostic model. Methods: The Cancer Genome Atlas (TCGA) and FerrDb databases were used to collect RNA sequencing data of OC patients and ferroptosis-related genes, respectively. OC patients were randomly assigned to the training or testing set. Pearson correlation analysis was used to identify ferroptosis-related lncRNAs. Univariate Cox, Least Absolute Shrinkage and Selection Operator (LASSO), and multivariate regression analyses were performed in the training set to develop a predictive model. The model was validated in the testing set and entire set. Survival analysis, receiver operating characteristic curves, independent prognostic factor analysis, and correlation analysis with clinical features were performed to evaluate the predictive value of the model. A nomogram was established to predict the survivability of OC patients over 1, 3, and 5 years. The distribution of distinct groups was investigated using principal component analysis, and the underlying the biological functions were explored using gene set enrichment analysis. Results: Eleven ferroptosis-related lncRNAs were determined to establish the prognostic model. Patients in the high-risk group had poor prognosis compared with the low-risk group in the training, testing and entire sets. The area under the receiver operating characteristic curve corresponding to 1-, 3-, and 5-year survival were 0.731, 0.796, and 0.805 in the training set; 0.704, 0.597, and 0.655 in the testing set; and 0.715, 0.691, and 0.736, in the entire set, respectively. The risk score correlated with age and grade. The risk score was also an independent prognostic factor in OC. A nomogram with high C-index (0.68) was constructed. An intuitive observation of the principal component analysis revealed a distinction between high-and lowrisk groups, and gene set enrichment analysis indicated that cancer-related pathways were enriched in the high-risk group. Conclusions: The signature composed of 11 ferroptosis-related lncRNAs accurately predicted the prognosis of OC patients.

show abstract

“…Specifically, higher expression of LINC00152 in children with B-ALL was associated with a higher risk of early relapse; conversely, lower expression of LINC01013 was associated with early relapse. The lncRNA LINC00152 is also known as CYTOR (long non-coding RNA cytoskeleton regulator RNA) and has been previously described as an oncogenic lncRNA in many different types of cancer (e.g., [92][93][94][95][96][97]) and may serve as a potential biomarker for cancer detection in both solid tumor tissue and plasma [98,99]. Overall, these reports indicate that lncRNA expression can serve as useful biomarkers in B-ALL.…”

Section: Long Non-coding Rnas In Progenitor B-cell Acute Lymphoblastimentioning

confidence: 99%

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Rodriguez¹,

Paculova²,

Kogut³

et al. 2021

Preprint

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) comprise a diverse class of non-protein coding transcripts that regulate critical cellular processes associated with cancer. Advances in RNA-sequencing (RNA-Seq) have led to the characterization of non-coding RNA expression across different types of human cancers. Through comprehensive RNA-Seq profiling, a growing number of studies demonstrate that ncRNAs, including long non-coding RNA (lncRNAs) and microRNAs (miRNA), play central roles in progenitor B-cell Acute Lymphoblastic Leukemia (B-ALL) pathogenesis. Furthermore, due to their central roles in cellular homeostasis and their potential as biomarkers, the study of ncRNAs continues to provide new insight into the molecular mechanisms of B-ALL. This article reviews the ncRNA signatures reported for all B-ALL subtypes, focusing on technological developments in transcriptome profiling and recently discovered examples of ncRNAs with biologic and therapeutic relevance in B-ALL.

show abstract

LINC00152 Promotes Tumor Progression and Predicts Poor Prognosis by Stabilizing BCL6 From Degradation in the Epithelial Ovarian Cancer

Cited by 14 publications

References 36 publications

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

A ferroptosis-related lncRNA signature predicts prognosis in ovarian cancer patients

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About